- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT03455491
Study to Assess Efficacy and Safety of XC221 in the Treatment of Influenza and Other Acute Respiratory Viral Infections
Multicenter Double-blinded Placebo-Controlled Parallel-Group Randomized Clinical Trial of Efficacy, Safety and Choice of an Optimum Dose of XC221 in the Treatment of Influenza and Other Acute Respiratory Viral Infections in Adults
A multicenter double-blinded, randomized, placebo-controlled, parallel-group comparative Phase II clinical study to assess safety, tolerability, efficacy and optimal dose of XC221 vs. placebo in patients with uncomplicated influenza or other ARVI during a 3-day treatment.
The primary objective of the study is to demonstrate the difference in time before the onset of a sustained improvement in clinical symptoms according to the Modified Jackson Scale for ARVI and to determine the optimal dose of XC221 in the treatment of influenza and other ARVI.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
11 Russian centers were planned for participation in this study. The study consists of three periods: screening, treatment and follow-up.
All eligible patients will be randomized into 3 groups (groups A, B and C) in a 1:1:1 ratio:
Group A - XC221 100 mg daily (40 patients); Group B - XC221 200 mg daily (40 patients); Group C - Placebo (40 patients).
During the treatment period (3 days), patients will receive XC221 / placebo daily on a background of standard symptomatic therapy. The follow-up period lasts for 11 days.
Type d'étude
Inscription (Réel)
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
-
Izhevsk, Fédération Russe, 426063
- City Clinical Hospital №9
-
Krasnodar, Fédération Russe, 350063
- Kuban State Medical University
-
Rostov-on-Don, Fédération Russe, 344000
- City Clinical Hospital №1 n.a. Semashko
-
Ryazan', Fédération Russe, 390026
- Ryazan State Medical University n.a. Pavlov
-
Saint Petersburg, Fédération Russe, 190103
- The Center for Prevention and Fight about AIDS and Infectious Diseases
-
Saint Petersburg, Fédération Russe, 197110
- The Consulting and Diagnostic Center with out-patient help of the Administration of the President of the Russian Federation
-
Saint Petersburg, Fédération Russe, 197376
- Research Institute of Influenza
-
Saint Petersburg, Fédération Russe, 197706
- City Clinical Hospital №40 of Kurortny District
-
Saransk, Fédération Russe, 430024
- Mordovia State Medical University n.a. N.P.Ogarev, Clinical site - Republic Infectious Clinical Hospital
-
Volgograd, Fédération Russe, 400131
- Volgograd State Medical University, Clinical site - Infectious Regional Clinical Hospital № 1
-
Yaroslavl, Fédération Russe, 150007
- Сlinical Hospital №3
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Men and women aged 18 to 45 years (inclusively).
- Clinically diagnosed influenza or ARVI.
- Patient's body temperature ≥37.5ºС and at least 1 symptom from Modified Jackson Scale estimated more than 2 points.
- Uncomplicated course of influenza or ARVI based on clinical estimations.
- The first 36 hours from the beginning of symptoms of influenza or ARVI.
- Women of reproductive age (who are not in menopause and who have not undergone surgical sterilization) and men who have sexual activity should use a reliable method of contraception (acceptable methods of contraception in this study are: intrauterine devices, oral contraceptives, contraceptive patch, long-acting injectable contraceptives, a double barrier method (condom and diaphragm with spermicide) throughout the study period.
- Compliance with the treatment regimen, visits and laboratory examinations provided by the protocol.
- Signed Informed Consent Form.
Exclusion Criteria:
- Existence of complications of influenza or ARVI (including the presence / development of bacterial infection).
- Hypersensitivity to excipients of the drug XC221 or placebo.
- Antiviral medications in 7 days prior to screening (antiviral agents, interferons and interferon inducers, drugs that have immunomodulating action) or anti-infective agents of systemic or local action.
- Severe infection with signs of cardiovascular insufficiency development and other manifestations of infectious-toxic shock, as well as with the presence of neuroinfection syndrome (encephalic and meningoencephalic reactions, polyradiculoneuritis, neuritis).
- Signs of the development of viral pneumonia (the presence of two or more of the following symptoms): dyspnea, chest pain when coughing, systemic cyanosis, dullness of percussion sound with a symmetrical evaluation of the upper and lower sections of the lungs).
- Infectious diseases during the last week before including into the study.
- History of bronchial asthma.
- History of increased convulsive activity.
- Severe, decompensated or unstable somatic diseases (any diseases or conditions that are life-threatening or may worsen the patient's prognosis, and make him/her ineligible for the clinical study).
- History of oncological diseases, HIV, tuberculosis.
- Diabetes mellitus.
- Drug or alcohol abuse.
- Participation in any other clinical trial in the last 90 days.
- Pregnancy or lactation.
- Military or prison populations.
- Impossibility or inability to comply with the study procedures.
- A member of the investigator's family or other person interested in the results of the study.
- Abnormal laboratory results, which, according to the study doctor, interfere with the patient's inclusion in the study.
- History of renal insufficiency.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: XC221 100 mg
XC221 100 mg orally. 1 tablet of XC221 100 mg +1 tablet of Placebo 100 mg (in total 2 tablets) once daily during 3 days of treatment period |
once daily during 3 days.
|
Expérimental: XC221 200 mg
XC221 200 mg orally. 2 tablets of XC221 100 mg once daily during 3 days of treatment period
|
once daily during 3 days.
|
Comparateur placebo: Placebo
Placebo orally. 2 tablets of Placebo 100 mg once daily during 3 days of treatment period
|
once daily during 3 days.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Time to Sustained Improvement in Clinical Symptoms Based on Modified Jackson Scale for ARVI
Délai: From the time of randomization up to Day 14
|
The time before the onset of sustained improvement in clinical symptoms according to the Modified Jackson Scale (no more than 1 point for each symptom), measured in hours from the moment of the first dose of the drug. Modified Jackson Scale measures individuals' subjective ratings the severity of 12 respiratory symptoms. Ranges for each symptom: 0 points (no symptoms) - 3 points (the most severe). Total score (ranges from 0 to 32 points) is a sum of the point for each symptom. |
From the time of randomization up to Day 14
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Time to Body Temperature Normalization
Délai: From the time of randomization assessed up to Day 14
|
Time to body temperature normalization since treatment initiation, measured in hours (normalization is regarded as setting of body temperature below 37°C without elevation above these values)
|
From the time of randomization assessed up to Day 14
|
Percentage of Patients With Complications
Délai: From the time of randomization up to Day 14
|
The percentage of patients with complications of influenza/acute viral URI
|
From the time of randomization up to Day 14
|
The Area Under the Curve "Modified Jackson Scale Score" During 3-day Therapy
Délai: From randomization up to 3 days of treatment
|
Modified Jackson Scale measures individuals' subjective ratings the severity of 12 respiratory symptoms.
Ranges for each symptom: 0 points (no symptoms) - 3 points (the most severe).
Total score (ranges from 0 to 32 points) is a sum of the point for each symptom.
|
From randomization up to 3 days of treatment
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- ARI-XC221-02
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Grippe
-
Mitsubishi Tanabe Pharma CorporationComplété
-
Jiangsu Province Centers for Disease Control and...Royal (Wuxi) Biological Co., LTDComplétéGroupe A, C Méningite polysaccharidique | Haemophilus Influenza de type bChine
-
Jiangsu Province Centers for Disease Control and...Chengdu Olymvax Biopharmaceuticals Inc.Complété
-
University Hospital, LilleCSL Behring; Laboratoire français de Fractionnement et de Biotechnologies; O... et autres collaborateursRésiliéInfections pneumococciques | Pneumonie bactérienne | Méningite bactérienne | Otite moyenne | Infection chronique des sinus | Infection streptococcique | Déficit en anticorps | Carence en complément | Infections à Neisseria | Haemophilus InfluenzaFrance
-
QIAGEN Gaithersburg, IncComplétéInfections par le virus respiratoire syncytial | Grippe A | Rhinovirus | Grippe B | Panneau avancé QIAGEN ResPlex II | Infection due au virus parainfluenza humain 1 | Parainfluenza de type 2 | Parainfluenza de type 3 | Parainfluenza de type 4 | Métapneumovirus humain A/B | Virus/échovirus Coxsackie | Adénovirus... et d'autres conditionsÉtats-Unis
Essais cliniques sur XC221 100 mg
-
Valenta Pharm JSCComplétéEn bonne santéFédération Russe
-
Valenta Pharm JSCComplétéGrippe | Infection respiratoire virale | Infections virales aiguës des voies respiratoires supérieuresFédération Russe
-
PHARMENTERPRISES LLCComplétéGrippe | Infection respiratoire aiguëFédération Russe
-
Valenta Pharm JSCComplétéGrippe | Infection virale respiratoireFédération Russe
-
RSV Therapeutics LLCComplétéInfection au Sars-CoV-2Fédération Russe
-
RSV Therapeutics LLCComplétéInfection par le SRAS-CoV-2Fédération Russe
-
PHARMENTERPRISES LLCRSV Therapeutics LLCComplétéGrippe | Infections virales respiratoires aiguësFédération Russe
-
OrthoTrophix, IncComplété
-
AstraZenecaComplétéAntagoniste du récepteur de chimiokine 2 (CXCR2)Royaume-Uni
-
NEURALIS s.a.RecrutementPharmacocinétique | SécuritéBulgarie